Granules India Limited

• Granules India Faces US FDA Inspection At Gagillapur Facility
  Sahi · 19 Oct 2026
• GRANULES Outlook for the Week
  Equitypandit · 16 Oct 2026
• Granules India Plans INR 2,000 Cr Investment to Scale Complex Generics, Oncology & Peptide CDMO
  Digital Health News · 08 Oct 2026
• Granules India eyes potential 180-day US exclusivity for Ruxolitinib ER
  Indian Pharma Post · 08 Oct 2026
• Granules India plans ₹2k cr investment to drive growth
  pharma.economictimes.indiatimes.com · 08 Oct 2026
• Granules India files Paragraph IV certification for Ruxolitinib Extended-Release Tablets
  Express Pharma · 07 Oct 2026
• Granules eyes first to file status, 180 days exclusivity on generic cancer drug Ruxolitinib in U.S.
  The Hindu · 07 Oct 2026
• Granules India expecting sole first to file status on Ruxolitinib Extended-Release Tablets
  TradingView · 07 Oct 2026
• Buy Granules India; target of Rs 1010: Choice Institutional Equities
  Moneycontrol.com · 05 Oct 2026
• Granules India incorporates wholly owned subsidiary in Brazil
  CNBC TV18 · 02 Oct 2026
• Granules India incorporates wholly owned subsidiary in Brazil
  scanx.trade · 02 Oct 2026
• Marksans Pharma vs Jubilant Pharmova vs Granules India: Compariso
  Univest · 25 Sep 2026

Headlines from the last 30 days, linking to the original publishers. See all market news →